however, it is hypothesised based largely on preclinical and early clinical data that glucagon receptor agonism, in the context of GLP-1 co-stimulation, may increase energy expenditure and promote fat breakdown (lipolysis), potentially amplifying weight loss beyond what is achievable with dual agonists alone
Floch F, Boissy L, Lanore D, Sayag D, Serres F
FDA authorization means the product met standards for quality, safety, and effectiveness
All clinical trial data and research results presented on this page are from peer-reviewed scientific journals and official publications
For type 2 diabetes, GLP1s such as Ozempic, Rybelsus, Victoza, Trulicity and Mounjaro are commonly prescribed when lifestyle changes or metformin arent enough